The societal opportunities and challenges of genome editing

Genome Biology

Volumn 16, Issue 1, 2015, Pages

  Carroll, Dana ^a   Charo, R Alta ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN LAW SCHOOL   (United States)

Author keywords

CRISPR Cas; Ethical issues; Food and Drug Administration; Genetically engineered organism; Germline genome editing; Regulation

Indexed keywords

AGRICULTURE; ARTICLE; BREEDING; CELL TRANSFER; DNA END JOINING REPAIR; FERTILIZATION IN VITRO; GENE CONVERSION; GENE INACTIVATION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING AND GENE TECHNOLOGY; GENETIC MANIPULATION; GENETIC REGULATION; GENETIC VARIABILITY; GENOME EDITING; GERM LINE; GOVERNMENT REGULATION; HUMAN; LIVESTOCK; MEDICAL ETHICS; MEDICINE; NONHUMAN; SAFETY; SOCIAL ASPECT; TRANSGENIC ORGANISM; CRISPR CAS SYSTEM; GENETIC ENGINEERING; GENETICS; HUMAN GENOME; RNA EDITING; TRENDS;

AGRICULTURE; CRISPR-CAS SYSTEMS; GENETIC ENGINEERING; GENOME, HUMAN; HUMANS; MEDICINE; RNA EDITING;

EID: 84946402356     PISSN: 14747596     EISSN: 1474760X     Source Type: Journal    
DOI: 10.1186/s13059-015-0812-0     Document Type: Article

References (48)

1. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816-21.
2. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096.
3. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157:1262-78.
4. Segal DJ, Meckler JF. Genome engineering at the dawn of the golden age. Annu Rev Genomics Hum Genet. 2013;14:135-58.
5. Carroll D. Genome engineering with targetable nucleases. Annu Rev Biochem. 2014;83:409-39.
6. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014;15:321-34.
7. Koo T, Lee J, Kim JS. Measuring and reducing off-target activities of programmable nucleases including CRISPR-Cas9. Mol Cells. 2015;38:475-81.
8. Foley JA, Ramankutty N, Brauman KA, Cassidy ES, Gerber JS, Johnston M, et al. Solutions for a cultivated planet. Nature. 2011;478:337-42.
9. Baltes NJ, Voytas DF. Enabling plant synthetic biology through genome engineering. Trends Biotechnol. 2015;33:120-31.
10. Tan WS, Carlson DF, Walton MW, Fahrenkrug SC, Hackett PB. Precision editing of large animal genomes. Adv Genet. 2012;80:37-97.
11. Medugorac I, Seichter D, Graf A, Russ I, Blum H, Göpel KH, et al. Bovine polledness - an autosomal dominant trait with allelic heterogeneity. PLoS One. 2012;7, e39477.
12. Tan W, Carlson DF, Lancto CA, Garbe JR, Webster DA, Hackett PB, et al. Efficient nonmeiotic allele introgression in livestock using custom endonucleases. Proc Natl Acad Sci U S A. 2013;110:16526-31.
13. McPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci U S A. 1994;94:12457-61.
14. Huang X-J, Zhang H-X, Wang H, Xiong K, Qin L, Liu H. Disruption of the myostatin gene in porcine primary fibroblasts and embryos using zinc-finger nucleases. Mol Cells. 2014;37:302-6.
15. Luo J, Song Z, Yu S, Cui D, Wang B, Ding F, et al. Efficient generation of myostatin (MSTN) biallelic mutations in cattle using zinc finger nucleases. PLoS One. 2014;9, e95225.
16. Cyranoski D. Super-muscly pigs created by small genetic tweak. Nature. 2015;523:13-4.
17. Patterson LA, Josling T. Regulating biotechnology: comparing EU and US approaches. European Policy Papers 8, Archive of European Integration. 2003. http://aei.pitt.edu/28/.
18. Anderson K, Jackson LA. Why are US and EU policies toward GMOs so different? AgBioForum. 2003;6:95-100.
19. Papademetriou T. Restrictions on genetically modified organisms: European Union. Law Library of Congress. 2015. http://www.loc.gov/law/help/restrictions-on-gmos/eu.php.
20. Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab. 2009;96:151-7.
21. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185-93.
22. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415-9.
23. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther. 2012;20:1831-2.
24. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370:901-10.
25. Walters L, Palmer JG. The Ethics of Human Gene Therapy. New York: Oxford University Press; 1997.
26. Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, et al. A prudent path forward for genomic engineering and germline gene modification. Science. 2015;348:36-8.
27. Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J. Don't edit the human germ line. Nature. 2015;519:410-1.
28. Dzau VJ, Cicerone RJ. Responsible use of human gene-editing technologies. Hum Gene Ther. 2015;26:411-2.
29. Liu H, Chen Y, Niu Y, Zhang K, Kang Y, Ge W, et al. TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. Cell Stem Cell. 2014;14:323-8.
30. Niu Y, Shen B, Cui Y, Chen Y, Wang J, Wang L, et al. Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell. 2014;156:836-43.
31. Chen Y, Zheng Y, Kang Y, Yang W, Niu Y, Guo X, et al. Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. Hum Mol Genet. 2015;24:3764-74.
32. Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Prot Cell. 2015;6:363-72.
33. Portmore DW. Commonsense consequentialism: wherein morality meets rationality. New York: Oxford University Press; 2011.
34. Jordan A, O'Riordan T. The precautionary principle: a legal and policy history. In: Martuzzi M, Tickner JA, editors. The precautionary principle: protecting public health, the environment and the future of our children. Rome: World Health Organization; 2004. p. 31-48.
35. Epstein CJ. Is modern genetics the new eugenics? Genet Med. 2003;5:469-75.
36. Center for Genetics and Society. About human germline gene editing. 2015. http://www.geneticsandsociety.org/article.php?id=8711.
37. Mawer S. Mendel's dwarf. New York: Harmony Publishing; 1998.
38. National Bioethics Advisory Commission meeting transcript. March 13, 1997. http://bioethics.georgetown.edu/nbac/transcripts/1997/3-13-97.pdf.
39. Engelhardt Jr HT. Global bioethics, theology, and human genetic engineering: the challenge of refashioning human nature in the face of moral and religious pluralism. In: Pfleiderer G, Brahier G, Lindpaintner K, editors. GenEthics and Religion. Basel: Karger; 2010. p. 40-51.
40. Brown E. The dilemmas of German bioethics. The New Atlantis. 2004;5:37-53.
41. Berthiau T. Law, bioethics and practice in France: forging a new legislative pact. Med Health Care Philos. 2013;16:105-13.
42. Human Fertilization and Embryology Authority (HFEA). http://www.hfea.gov.uk/.
43. The Hinxton Group. Statement on genome editing technologies and human germline genetic modification. September 4, 2015. http://www.hinxtongroup.org/Hinxton2015_Statement.pdf.
44. BBC News. Scientists seek permission to genetically modify embryos. http://www.bbc.com/news/health-34288659. Accessed: 15 Oct 2015.
45. Esvelt KE, Smidler AL, Catteruccia F, Church GM. Concerning RNA-guided gene drives for the alteration of wild populations. eLife. 2014;3, e03401.
46. Burt A. Site-specific selfish genes as tools for the control and genetic engineering of natural populations. Proc Biol Sci. 2003;270:921-8.
47. Oye KA, Esvelt K, Appleton E, Catteruccia F, Church G, Kuiken T, et al. Regulating gene drives. Science. 2014;345:626-8.
48. Gantz VM, Bier E. The mutagenic chain reaction: a method for converting heterozygous to homozygous mutations. Science. 2015;348:442-4.